**Latin American Journal of Clinical Sciences and Medical Technology is an open access magazine.

To read all published articles and materials you just need to register

Registration is free of charge.   Register now

If you already have registered please   Log In
**
Tuesday May 24th, 2022
Latin American Journal of Clinical Sciences and Medical Tecnology
Partnerships
DADI Salud
Previous Volume
Current Volume
Submit & Guides for Authors
Authors / Reviewers Access
Editorial Board
Register
Log In
Mission. To accessibly present interesting topics and original research in clinical sciences by means of procedures and digital technology which are friendly for authors, reviewers, and the reader.
Vision. To create a forum to discuss relevant topics and to spread out the original clinical research produced in Latin America. In that way, we will foster the development of high-quality research and publication in Latin-America in order to make visible the expertise and evidence our clinicians all over the world.
Objective. To be an effective and state-of-the-art tool for spreading Latin American original research with the best visibility, availability, and legibility that will ensure an increase in the number, quality and citation of the Latin American region. Based on that, our journal will contribute to improve the comprehension of basic concepts for the use of the latest diagnosis and treatment resources.
Latin American Journal of Clinical Sciences and Medical Technology is an international, Open Access magazine, which continuously publishes articles in Spanish and in English, and it is spread out online and in printed versions. It is a scientific, academic tool focused on original Latin-American research, as well as on subjects of interest that will undoubtedly enrich the continuing medical education in the aforementioned geographical area.

Papel del científico en América Latina y el Caribe: promover la cultura de publicación entre los jóvenes

Gilberto Castañeda Hernández, Edgar López-López

Uno de los principales objetivos de la ciencia es desarrollar nuevo conocimiento. Sin embargo, éste no sólo debe generarse, también debe comunicarse. Es decir, no publicar nuestros resultados es equivalente a nunca haberlos generado. En este sentido, la publicación de resultados es una de las principales labores y responsabilidades del científico. Existen múltiples razones para hacerlo1, por ejemplo:

  • Promover el avance y aplicación de un nuevo conocimiento
  • Generar un efecto positivo (directo o indirecto) en la sociedad
  • Recibir otros beneficios relacionados con la mejora de la trayectoria académica, profesional y personal de cada autor
Learn more

Attainment of Best Practice Recommendations and Late Complications of Patients with Type 1 and Type 2 Diabetes Mellitus

Fernando Lavalle-González, Maricela Vidrio-Velázquez, Rutila Castañeda-Limones, Paloma Almeda-Valdés, Liz Toapanta-Yanchapaxi, Ana Ochoa-Guzmán, Erwin Chiquete

Background: There is a need for information on the current practices of diabetes management to take some actions and improve the attainment of therapeutic goals. Objective. We aimed to describe the attainment of therapeutic targets and late complications of patients with type 1 (T1D) and type 2 (T2D) diabetes mellitus. Material and Methods. In the fourth wave of the International Diabetes Management Practices Study, 1,966 Mexican patients were analyzed (T1D: n=157, 8%; T2D: n=1809, 92%). The cross-sectional phase regarding metabolic profile, current complications, and management are analyzed. Results. Out of T1D patients, 77.6% received insulin alone, and 27.4% had insulin and oral glucose-lowering drugs (OGLD, mostly metformin). Out of T2D patients, 63% received OGLD exclusively (mostly metformin), 4.3% insulin alone, 30.4% OGLD, and insulin, and 2% were on a diet and exercise exclusively. Only 19.7% T1D and 35.9% T2D patients had HbA1c <7% (p=0.01), and only 5.0% of T1D and 3.9% of T2D met the combined therapeutic target of HbA1c <7% + BP <130/80 mmHg + LDL <100 mg/dl. Late diabetes-related complications occurred in 42.7% of T1D and 52.8% of T2D patients, mostly microvascular disease. Macrovascular complications were more frequent in patients with T2D, as compared with T1D (36.8% vs. 16.4%, p<0.001). The number of late complications increased steadily with disease duration, more pronounced in patients with T2D. Conclusions. This study evidences substantial lags in the attainment of clinical goals of patients with diabetes mellitus. There are noticeable differences in the achievement of current therapeutic targets between patients with T1D and T2D in a sample of the Mexican practice.

Learn more

SARS-CoV-2 Pneumonia after Allogenic Stem Cell Transplantation Successfully Treated with JAK1/2 Inhibitor

Roberto Ovilla-Martínez , Nishalle Ramírez-Muñiz, Andric Cuevas-Juárez, Pamela E. Báez-Islas

Allogeneic stem cell transplantation is one of the most immunosuppressive states in transplantation, mainly in the first year post-transplant. In the COVID-19 pandemic, this group of patients is at increased risk of mortality and morbidity due to a more vulnerable immune system. Even with the new vaccines against SARS-CoV-2, the availability to build a vaccine-induced immune response that could protect against the virus infection is unclear as the immune responses are blocked by the immunosuppressive drugs used in these patients (and according to some studies, in patients with hematological malignancy). Based on this background, effective therapies against COVID-19 in patients post-transplant are mandatory. Herein, we report the case of a patient with acute lymphoblastic leukemia (after haploidentical bone marrow transplantation) who successfully responded to COVID-19 pneumonia with the JAK1/2 inhibitor, ruxolitinib.

Learn more

All Rights Reserved® 2019

Latin American Journal of Clinical Sciences and Medical Technology,
Año 1, No. 1, octubre, 2019 es una publicación contínua editada por Vesalio S.C.; http://www.lajclinsci.com/    Editor responsable: Gilberto Castañeda Hernández.    Reserva de Derechos al Uso Exclusivo: 04-2019-062013242000-203; ISSN: 2683-2291; ambos otorgados por el Instituto Nacional del Derecho de Autor.    Responsable de la última actualización de este número, Web Master Hunahpú Velázquez Martínez,
Calle San Luis Potosí #182-1, Col. Roma, Alcaldía Cuauhtémoc, C.P. 06700, Ciudad de México; teléfono: 55 64 40 41    Fecha de última modificación, 30 de marzo de 2020.
Contact us   |   Privacy policy   |   Legal Information

All Rights Reserved® 2019

Latin American Journal of Clinical Sciences and Medical Technology,
Año 1, No. 1, octubre, 2019 es una publicación contínua editada por Vesalio S.C.; http://www.lajclinsci.com/    Editor responsable: Gilberto Castañeda Hernández.    Reserva de Derechos al Uso Exclusivo: 04-2019-062013242000-203; ISSN: 2683-2291; ambos otorgados por el Instituto Nacional del Derecho de Autor.    Responsable de la última actualización de este número, Web Master Hunahpú Velázquez Martínez,
Calle San Luis Potosí #182-1, Col. Roma, Alcaldía Cuauhtémoc, C.P. 06700, Ciudad de México; teléfono: 55 64 40 41    Fecha de última modificación, 30 de marzo de 2020.